Innate Pharma 6-K Filing Incorporates by Reference

Ticker: IPHYF · Form: 6-K · Filed: Apr 24, 2025 · CIK: 1598599

Innate Pharma SA 6-K Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHYF)
Form Type6-K
Filed DateApr 24, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, registration-statement, administrative

TL;DR

Innate Pharma files 6-K, incorporating info into F-3. CEO quote excluded.

AI Summary

Innate Pharma S.A. filed a Form 6-K on April 24, 2025, to incorporate by reference information into its Form F-3 registration statement (File No. 333-276164). This filing includes Exhibit 99.1, which contains a quotation from CEO Jonathan Dickinson, though the quotation itself is excluded from the incorporation by reference.

Why It Matters

This filing is a procedural step for Innate Pharma to update its registration statement, potentially facilitating future capital raises or other securities transactions.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

  • Innate Pharma S.A. (company) — Registrant
  • Jonathan Dickinson (person) — CEO of Innate Pharma
  • Form F-3 (File No. 333-276164) (document) — Registration statement being updated
  • April 24, 2025 (date) — Date of report

FAQ

What is the purpose of this Form 6-K filing?

The purpose is to incorporate by reference information, specifically Exhibit 99.1 (excluding a CEO quotation), into Innate Pharma's existing registration statement on Form F-3 (File No. 333-276164).

What is the filing date of this Form 6-K?

The filing date is April 24, 2025.

Which registration statement is being updated by this filing?

The registration statement on Form F-3 with File Number 333-276164 is being updated.

Is the quotation from the CEO, Jonathan Dickinson, included in the incorporation by reference?

No, the quotation from Jonathan Dickinson, Chief Executive Officer at Innate Pharma, is explicitly excluded from the incorporation by reference.

What type of company is Innate Pharma S.A.?

Innate Pharma S.A. is classified under the Standard Industrial Classification code 2836, which pertains to Biological Products (No Diagnostic Substances).

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 24, 2025 by Jonathan Dickinson regarding Innate Pharma SA (IPHYF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.